Amyloid beta-protein 3(pE)-42 antibodies and uses thereof

Details Amyloid beta-protein 3(pE)-42 antibodies and uses thereof Amyloid beta-protein 3(pE)-42 antibodies and uses thereof

2006-10-17

2006-10-17

Andres, Janet L. (Department: 1649)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Animal cell, per se, expressing immunoglobulin, antibody, or...

C435S346000, C530S388100, C530S387300, C424S141100, C424S133100, C424S134100, C424S135100, C424S139100

Reexamination Certificate

active

07122374

ABSTRACT:
AβN3pE-42is a β amyloid protein that accumulates specifically as a major constituent of senile plaque in the brains of both sporadic and familial Alzheimer's disease patients. The invention provides antibodies that specifically recognize AβN3pE-42and can be expected to have a strong β amyloid-removing action. Particularly, humanized antibodies against AβN3pE-42are useful to treat human neurodegenerative diseases. Further, since AβN3pE-42is localized in the brain, the antibodies of the invention can avoid side effects such as kidney disorders caused by the formation of antigen-antibody complex in the blood. An agent for gene therapy using a vector in which a cDNA encoding a protein comprises the antigen-binding region of the antibody can be an efficient therapeutic drug for removing β amyloid from the brain.

REFERENCES:
patent: 5750349 (1998-05-01), Suzuki et al.
Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, New York, 1988, pp. 141-142, 287, 500-501.
Saido TC et al. Dominant and differential deposition of distinct beta-amyloid peptide species, AbetaN3(pE), in senile plaques, Neuron, Feb. 1995, 14:457-466.
Harigaya et al., 2000, “Amyloid β Protein Starting Pyroglutamate at Position 3 . . . ”Biochem. Biophys. Res. Commun. 276:422-427.
Kamiya Biomedical Companyproduct data sheet for β-Amyloid (1-42) peptide (May 5, 2001).
Pardridge, “Targeting Protein Therapeutics and Gene . . . ”, 2001, Seitai no Kagaku, vol. 52(6):577-83.
Temsamani et al., “Brain drug delivery technologies: . . . ”, 2000, Pharm. Sci. & Tech. Today, vol. 3(5):155-62.
Rousselle et al., “New Advances in the Transport of . . . ”, 2000, Mol. Pharmacol., vol. 57(4):679-86.
Saido, 1997, Shinkei-Shinpo, vol. 41(1): 58-69 (English abstract on p. 69).
Synt-em pamphlet, “A closer look at Pep:trans”, 2001.
Kaneko I et al., 2000, Molecular Medicine, vol. 37(9);1030-42, along with 2-page concise English language explanation of reference.

Affiliated with

Also associated with

Rating

Amyloid beta-protein 3(pE)-42 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amyloid beta-protein 3(pE)-42 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amyloid beta-protein 3(pE)-42 antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3646350